Table 2. Changes in absolute values of non-invasive tests over time.

	LFS†‡		LAP†‡		NFS†‡		FIB-4†‡
Visits (months)	Aleglitazar	Placebo	Aleglitazar	Placebo	Aleglitazar	Placebo	Aleglitazar	Placebo
0	N = 3,057 0.63 (0.57, 0.69)	N = 3,015 0.60 (0.56, 0.66)	N = 3,496 67.8 (66.2, 69.5)	N = 3,478 69.5 (67.3, 71.6)	N = 3,234 -0.41 (-0.45, -0.37)	N = 3,240 -0.50 (-0.56, -0.40)	N = 3,250 1.44 (1.42, 1.46)	N = 3,261 1.40 (1.38, 1.42)
3	N = 2,877 0.17 (0.13, 0.20)	N = 2,855 0.63 (0.57, 0.70)	Not available	Not available	N = 3,057 -0.59 (-0.63, -0.55)	N = 3,020 -0.29 (-0.33, -0.25)	N = 3,080 1.11 (1.09, 1.13)	N = 3,047 1.41 (1.39, 1.43)
6	N = 2,743 0.19 (0.16, 0.23)	N = 2,761 0.66 (0.59, 0.72)	N = 3,066 51.0 (49.2, 52.8)	N = 3,096 78.3 (75.5, 81.0)	N = 2,909 -0.54 (-0.58, -0.50)	N = 2,943 -0.31 (-0.35, -0.27)	N = 2,931 1.10 (1.08, 1.12)	N = 2,964 1.39 (1.37, 1.41)
12	N = 2,620 0.20 (0.15, 0.23)	N = 2,674 0.68 (0.62, 0.74)	N = 2,932 55.4 (53.8, 57.0)	N = 2,994 80.4 (77.8, 83.0)	N = 2,765 -0.50 (-0.54, -0.46)	N = 2,818 -0.25 (-0.29, -0.21)	N = 2,786 1.10 (1.08, 1.12)	N = 2,840 1.44 (1.42, 1.46)
24	N = 1,634 0.22 (0.17, 0.28)	N = 1,707 0.67 (0.61, 0.75)	N = 1,725 60.7 (58.3, 63.1)	N = 1,783 83.8 (80.3, 87.4)	N = 1,720 -0.37 (-0.43, -0.31)	N = 1,799 -0.20 (-0.26, -0.14)	N = 1,731 1.16 (1.14, 1.18)	N = 1,817 1.47 (1.43, 1.51)

†LFS = liver fat score; LAP = liver accumulation product; NFS = Non-alcoholic fatty liver disease fibrosis score; FIB-4 = fibrosis 4 calculator.

‡ Values of LFS are presented as median (distribution free 95% CI) and values of LAP, NFS and FIB-4 as mean (95% CI).